Metacrine Inc. (fka MTCR)

[Renee]

MTCR: Liquidation/Final Distribution (no distribution notes by FINRA)

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

MTCR delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

[HoldEm777]

Insider buying and a buyout… may be already baked in but probably not.

[CrispCris]

Double down

[DewDiligence]

50% workforce reduction in R&D:

https://www.globenewswire.com/news-release/2022/02/11/2383703/0/en/Metacrine-Updates-IBD-Clinical-Development-Strategy-and-Implements-Restructuring-Plan.html

What took so long?

[pitacorp]

you sure hit the nail on the head with that brilliant conclusion... 4 month old news is going to make this dive now???

[KeepOn]

Something happening here?

[mining101]

Who is following that move??

[mining101]

Super bullish close

[JMoneyHoops]

Yes lost big unfortunately hopefully a bounce PM the love/hate of biotech plays

[DewDiligence]

MTCR addendum: #msg-166460862.

[DewDiligence]

MTCR -50%/AH on discontinuation of FXR/NASH program:

https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html

“After a rigorous assessment of our NASH and IBD programs, including the significant capital and resources required to progress these large clinical development programs, we have made the decision to focus Metacrine’s clinical development effort and financial resources on moving MET642 into a Phase 2 trial in IBD in the first half of 2022 and to halt future development of the FXR program in NASH. This decision was influenced in part by a potential delay in confirming appropriate safety margins in our long-term toxicology work that would impact the timing of future NASH studies, but is unlikely to impact timelines for the IBD clinical program.”

That was in the seventh paragraph of the PR, LOL.

[JMoneyHoops]

Data soon

[DewDiligence]

MTCR 1Q21 results—3/31/21_cash=$84.5M:

https://finance.yahoo.com/news/metacrine-accelerates-met409-clinical-development-200500397.html

[DewDiligence]

MTCR 4Q20 results—12/31/20 cash=$96.2M:

https://www.globenewswire.com/news-release/2021/03/18/2195229/0/en/Metacrine-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html

[DewDiligence]

MTCR starts phase-2a for MET642—the follow-on FXR agonist to MET409:

https://finance.yahoo.com/news/metacrine-initiates-phase-2a-trial-113000073.html

The Phase 2a clinical trial is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg) vs placebo. An interim analysis is planned in the fourth quarter of 2021, after approximately 60 patients have completed 16 weeks of treatment. Topline trial results of up to 180 patients are expected to be reported in the first half of 2022.

See #msg-162210410 for related info.

[DewDiligence]

MET-409 phase-1b data in NASH don’t look so good:

#msg-162210410

[doogdilinger]

Up +7% pm

[doogdilinger]

Awesome sauce crude buddy, catchin' up on the DD with ya ty

[doogdilinger]

Perfect! I'm playing way more big board this month than pennies! The money flow on big board runners has been utter insanity so far this month!

[doogdilinger]

Nice crude buddy;)

[crudeoil24]

IPO was last month > 9/16/2020.

[crudeoil24]

Metacrine shares are trading higher after the company announced it is presenting new data from its MET409 program in NASH at AASLD's The Liver Meeting Digital Experience.

[crudeoil24]

Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.